You are likely wondering what you’re missing, but it’s not you — it’s the system. Across the United States, Canada and United ...

Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine ...

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

With economic pressures limiting opportunities for students and new grads, local post-secondary schools are working with ...